Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Jaffer A. Ajani, Kuaile Zhao et al.|Journal of Clinical Oncology|2022Cited by 306
809MO Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphomaYufang Song, Jiahui Zhu, Kaixin Zhou et al.|Annals of Oncology|2024Cited by 1